Bavarian Nordic (BVNRY) Stock Forecast for 2024, 2025, 2026. Sell or Buy Prediction







Advanced Charting Tools For Traders

January 1, 2025 Advanced Charting Tools For Traders

Ever tried deciphering market trends with the intensity of a detective peering over cryptic clues? Enter the realm of Advanced Charting, where complex…
Why Is Trading Important?

December 21, 2024 Why Is Trading Important?

Trade isn’t just figures on a spreadsheet; it’s the pulse of our global community. In 2018, the United States faced a staggering $621…
Best AI Trading & Performance Tools

December 21, 2024 Best AI Trading & Performance Tools

Ever find yourself overwhelmed by the rapid twists and turns of the stock market? I know the feeling—one moment you’re riding high, and…
Best Economic Calendars For Traders

December 21, 2024 Best Economic Calendars For Traders

You know that feeling when a crucial financial announcement catches you off guard, and suddenly your trading plans are turned upside down? We’ve…
When to Switch Payroll Solutions and How to Make a Smooth Transition

December 9, 2024 When to Switch Payroll Solutions and How to Make a Smooth Transition

Payroll solutions are important for every business, as without them, you cannot make the right choices and calculations in your payment system. However,…

Bavarian Nordic (BVNRY) Stock Forecast for 2024, 2025, 2026. Sell or Buy?

Updated: January 20, 2025 (02:52)

Sector: Healthcare

The share price of Bavarian Nordic A/S (BVNRY) now

Latest session on the 17th of January for
Bavarian Nordic A/S is positive
Trading Volume: 536
Open: 9.008 /  High: 9.008 /  Low: 9.008
Current value: $9.008

Analysts predictions

Full report
This Week
Neutral Opinions: Na
Previous Week
Neutral Opinions: Na
Two Weeks Ago
Neutral Opinions: Na
Three Weeks Ago
Neutral Opinions: Na

Are you interested in Bavarian Nordic A/S stocks and want to buy them, or are they already in your portfolio? If yes, then on this page you will find useful information about the dynamics of the Bavarian Nordic stock price in 2025, 2026, 2027. How much will one Bavarian Nordic share be worth in 2025 - 2027?

When should I take profit in Bavarian Nordic stock? When should I record a loss on Bavarian Nordic stock? What are analysts' forecasts for Bavarian Nordic stock? What is the future of Bavarian Nordic stock? We forecast Bavarian Nordic stock performance using neural networks based on historical data on Bavarian Nordic stocks. Also, when forecasting, technical analysis tools are used, world geopolitical and news factors are taken into account.

Bavarian Nordic stock prediction results are shown below and presented in the form of graphs, tables and text information, divided into time intervals. (Next month, 2025, 2026, 2027, and ) The final quotes of the instrument at the close of the previous trading day are a signal to adjust the forecasts for Bavarian Nordic shares. This happens once a day.


Historical and forecast chart of Bavarian Nordic stock

The chart below shows the historical price of Bavarian Nordic stock and a prediction chart for the next month. For convenience, prices are divided by color. Forecast prices include: Optimistic Forecast, Pessimistic Forecast, and Weighted Average Best Forecast. Detailed values for the Bavarian Nordic stock price can be found in the table below.

Long-term forecasts by years.

Bavarian Nordic A/S Analysts predictions review

Bavarian Nordic (BVNRY) shows a cautiously optimistic outlook, driven by strong diversification efforts and government-backed demand for its vaccine portfolio. Key growth prospects stem from innovative respiratory vaccines (RSV and influenza), supported by strategic partnerships and commercialization initiatives. However, near-term risks include declining Mpox vaccine demand and execution challenges in portfolio expansion. Financial stability, marked by steady cash flow and operational efficiencies, enhances their ability to navigate short-term pressures, though rising debt levels merit monitoring. External macroeconomic risks, such as geopolitical factors and currency fluctuations, remain potential headwinds.

Positioning Bavarian Nordic for Growth: Vaccine Strengths and Revenue Projections for 2025

Trend: Bullish
Nov 19, 2024

Bavarian Nordic's robust vaccine portfolio is a central driver of its growth outlook, underpinned by its recognized expertise in immunology and infectious disease prevention. The company's advancements in key programs, such as its monkeypox and smallpox vaccines, solidify its competitive position, particularly in securing government and institutional contracts. According to the author, this provides a strong defensive moat within an expanding global market for preventive health solutions.

The projected revenue expansion by 2025 is grounded in strategic product launches and commercialization efforts, especially within the RSV and influenza markets. These high-growth therapeutic areas offer significant upside potential as Bavarian Nordic leverages its pipeline to gain market share, supported by increasing demand for innovative respiratory vaccines.

Revenue Diversification and Long-Term Drivers

Partnership agreements with large-cap pharmaceutical companies enhance the company's profile and mitigate risks associated with single-product dependency. Such collaborations reinforce Bavarian Nordic's research and development capabilities, enabling it to focus resources on high-yielding projects identified by the author as essential to future growth.

Macroeconomic factors, particularly government funding for public health initiatives, play a vital role in the company's trajectory. Any shifts in funding priorities could affect the valuation, but the current trend supports sustained investment in its product portfolio.


Analyst: Myriam Alvarez
( Followers: 2190
Articles: 243 )

Bavarian Nordic: Diversification Drives Stability Amid Waning Mpox Demand

Trend: Neutral
Nov 17, 2024

Bavarian Nordic's recent performance reveals a strategic shift, as the demand for its Mpox vaccine subsides. This decline in Mpox-related revenue highlights the company's vulnerability to overly specialized product reliance in the near term. However, the company's proactive measures to diversify its portfolio, particularly through advancements in infectious disease and oncology vaccines, significantly strengthen its long-term growth prospects. According to the author, this diversification could mitigate revenue volatility stemming from cyclical demand for its legacy products.

Portfolio Expansion as a Growth Catalyst

Another key factor discussed is Bavarian Nordic's recent partnerships and acquisitions aimed at enhancing its R&D pipeline. These collaborations position the company to stay competitive within the biopharmaceutical landscape and align with an industry-wide trend toward innovation through external synergies. While such investments require upfront capital, the author suggests that their long-term payoff is likely to outweigh short-term liquidity pressures.

Lastly, Bavarian Nordic’s financial health remains a crucial element of the analysis. The company’s ability to maintain stable operational cash flow, despite a revenue shift, underscores management's effectiveness in navigating market transitions. This stability serves as a foundation for executing its growth strategy, though investors should monitor any indications of rising leverage that could adversely affect shareholder value.


Analyst: Stephen Ayers
( Followers: 7833
Articles: 798 )

BVNRY: Assessing Investment Potential Amid Strategic Moves and Market Trends

Trend: Neutral
Aug 20, 2024

The article highlights BVNRY's strategic operational shifts as a key driver of its stock performance, emphasizing both opportunities and risks inherent to these changes. The company’s focus on expanding into higher-margin business segments positions it favorably for long-term growth, though execution risks remain significant in the near term, potentially causing volatility.

Operational Efficiency and Market Position

Another critical factor cited involves BVNRY's improved operational efficiencies, which have supported stable profitability despite prevailing macroeconomic challenges. This stabilization underscores the company's resilience, but its ability to sustain these improvements will likely determine the trajectory of future earnings growth.

The analysis also acknowledges external market dynamics as a mixed influence on BVNRY's valuation. Favorable demand trends in the company's primary markets provide upside potential, but geopolitical uncertainties and currency fluctuations are noted risks that could dampen near-term investor sentiment.


Analyst: Edmund Ingham
( Followers: 12877
Articles: 913 )
Aug 18, 2024
Bavarian Nordic: Strategic Jynneos Growth Drives Opportunities in Health Crisis Preparedness
Trend: Bullish

Bavarian Nordic A/S focuses on the development, manufacturing and commercialization of cancer immunotherapies and vaccines for infectious diseases. It specializes in cancer immunotherapy which includes cancer pipeline, which focuses on therapeutic vaccines for breast, lung, ovarian and prostate cancer. Its products include IMVAMUNE for Ebola, HPV, HBV, and HIV diseases. The company was founded in 1994 and is headquartered in Kvistgaard, Denmark.

Trending Themes in the Healthcare Sector

Bavarian Nordic daily forecast for a month

Date Target Pes. Opt. Vol., %
Jan 21 9.50 9.19 9.75 6.10
Jan 22 9.55 9.36 9.78 4.49
Jan 23 9.48 9.38 9.68 3.13
Jan 24 9.03 8.84 9.16 3.63
Jan 25 9.36 9.07 9.52 5.01
Jan 26 9.57 9.31 9.71 4.32
Jan 27 9.74 9.35 10.02 7.14
Jan 28 9.51 9.37 9.69 3.40
Jan 29 9.62 9.34 9.85 5.46
Jan 30 9.65 9.31 9.89 6.27
Jan 31 9.39 9.15 9.51 4.01
Feb 01 9.62 9.37 9.92 5.91
Feb 02 9.54 9.45 9.80 3.69
Feb 03 9.49 9.38 9.79 4.45
Feb 04 9.78 9.40 10.07 7.07
Feb 05 9.69 9.46 9.89 4.45
Feb 06 9.48 9.36 9.64 3.09
Feb 07 9.77 9.51 9.89 4.01
Feb 08 10.01 9.67 10.31 6.68
Feb 09 10.20 9.90 10.32 4.22
Feb 10 10.05 9.65 10.41 7.92
Feb 11 9.93 9.61 10.29 7.08
Feb 12 10.05 9.94 10.27 3.29
Feb 13 10.18 9.91 10.59 6.83
Feb 14 10.31 9.95 10.69 7.46
Feb 15 10.69 10.52 10.80 2.74
Feb 16 10.59 10.29 10.79 4.78
Feb 17 10.58 10.38 10.88 4.84
Feb 18 10.24 10.09 10.38 2.94
Feb 19 10.41 10.14 10.83 6.78

Bavarian Nordic Daily Price Targets


Bavarian Nordic Stock Forecast 01-21-2025.

Forecast target price for 01-21-2025: $9.50.
Positive dynamics for Bavarian Nordic shares will prevail with possible volatility of 5.748%.
Pessimistic target level: 9.19
Optimistic target level: 9.75

Bavarian Nordic Stock Forecast 01-22-2025.

Forecast target price for 01-22-2025: $9.55.
Positive dynamics for Bavarian Nordic shares will prevail with possible volatility of 4.297%.
Pessimistic target level: 9.36
Optimistic target level: 9.78

Bavarian Nordic Stock Forecast 01-23-2025.

Forecast target price for 01-23-2025: $9.48.
Negative dynamics for Bavarian Nordic shares will prevail with possible volatility of 3.038%.
Pessimistic target level: 9.38
Optimistic target level: 9.68

Bavarian Nordic Stock Forecast 01-24-2025.

Forecast target price for 01-24-2025: $9.03.
Negative dynamics for Bavarian Nordic shares will prevail with possible volatility of 3.499%.
Pessimistic target level: 8.84
Optimistic target level: 9.16

Bavarian Nordic Stock Forecast 01-25-2025.

Forecast target price for 01-25-2025: $9.36.
Positive dynamics for Bavarian Nordic shares will prevail with possible volatility of 4.769%.
Pessimistic target level: 9.07
Optimistic target level: 9.52

Bavarian Nordic Stock Forecast 01-26-2025.

Forecast target price for 01-26-2025: $9.57.
Positive dynamics for Bavarian Nordic shares will prevail with possible volatility of 4.140%.
Pessimistic target level: 9.31
Optimistic target level: 9.71

BVNRY (BVNRY) Monthly Stock Prediction for 2025

Month Target Pes. Opt. Vol., %
Feb. 8.47 7.84 9.75 19.62
Mar. 9.97 9.00 10.87 17.25
Apr. 10.77 9.63 12.02 19.89
May. 10.47 9.82 11.31 13.15
Jun. 10.24 9.11 11.04 17.44
Jul. 11.16 9.49 12.41 23.56
Aug. 12.41 11.10 13.98 20.60
Sep. 13.06 11.15 13.95 20.04
Oct. 14.13 12.80 15.34 16.57
Nov. 11.39 9.57 12.66 24.46
Dec. 10.75 10.30 12.15 15.22

Bavarian Nordic forecast for this year


Bavarian Nordic Stock Prediction for Feb 2025

An downtrend is forecast for this month with an optimal target price of $8.46705. Pessimistic: $7.84. Optimistic: $9.75


Bavarian Nordic Stock Prediction for Mar 2025

An uptrend is forecast for this month with an optimal target price of $9.97418. Pessimistic: $9.00. Optimistic: $10.87


Bavarian Nordic Stock Prediction for Apr 2025

An uptrend is forecast for this month with an optimal target price of $10.7721. Pessimistic: $9.63. Optimistic: $12.02


Bavarian Nordic Stock Prediction for May 2025

An downtrend is forecast for this month with an optimal target price of $10.4705. Pessimistic: $9.82. Optimistic: $11.31


Bavarian Nordic Stock Prediction for Jun 2025

An downtrend is forecast for this month with an optimal target price of $10.2401. Pessimistic: $9.11. Optimistic: $11.04


Bavarian Nordic Stock Prediction for Jul 2025

An uptrend is forecast for this month with an optimal target price of $11.1618. Pessimistic: $9.49. Optimistic: $12.41


Bavarian Nordic Stock Prediction for Aug 2025

An uptrend is forecast for this month with an optimal target price of $12.4119. Pessimistic: $11.10. Optimistic: $13.98


Bavarian Nordic Stock Prediction for Sep 2025

An uptrend is forecast for this month with an optimal target price of $13.0573. Pessimistic: $11.15. Optimistic: $13.95


Bavarian Nordic Stock Prediction for Oct 2025

An uptrend is forecast for this month with an optimal target price of $14.128. Pessimistic: $12.80. Optimistic: $15.34


Bavarian Nordic Stock Prediction for Nov 2025

An downtrend is forecast for this month with an optimal target price of $11.3872. Pessimistic: $9.57. Optimistic: $12.66


Bavarian Nordic Stock Prediction for Dec 2025

An downtrend is forecast for this month with an optimal target price of $10.7495. Pessimistic: $10.30. Optimistic: $12.15



Bavarian Nordic (BVNRY) Monthly Stock Prediction for 2026

Month Target Pes. Opt. Vol., %
Jan 8.71 7.92 9.80 19.18
Feb 9.35 8.38 9.82 14.67
Mar 10.45 9.79 11.40 14.13
Apr 11.71 11.24 12.67 11.28
May 12.79 11.12 14.70 24.35
Jun 14.24 12.68 15.78 19.68
Jul 16.24 15.20 17.93 15.22
Aug 16.27 14.64 17.80 17.73
Sep 13.93 11.81 14.88 20.60
Oct 12.28 11.30 14.15 20.14
Nov 11.62 9.99 12.39 19.32
Dec 12.11 11.60 13.08 11.30

Bavarian Nordic (BVNRY) Monthly Stock Prediction for 2027

Month Target Pes. Opt. Vol., %
Jan 12.98 11.89 13.63 12.76
Feb 13.73 12.14 14.42 15.81
Mar 14.48 13.09 16.07 18.56
Apr 16.62 14.89 18.08 17.65
May 15.39 13.36 17.33 22.91
Jun 13.73 12.35 14.50 14.77
Jul 11.26 10.02 12.31 18.65
Aug 9.23 8.86 10.19 13.04
Sep 10.96 9.34 12.43 24.87
Oct 10.96 10.50 12.37 15.07
Nov 12.00 11.20 13.03 14.00
Dec 14.18 11.91 15.37 22.51

Bavarian Nordic information and performance

Bavarian Nordic Address

N/A

Market Capitalization: N/A $

Market capitalization of the Bavarian Nordic A/S is the total market value of all issued shares of a company. It is calculated by the formula multiplying the number of BVNRY shares in the company outstanding by the market price of one share.

EBITDA: N/A $

EBITDA of Bavarian Nordic is earnings before interest, income tax and depreciation of assets.

PE Ratio: N/A

P/E ratio (price to earnings) - shows the ratio between the price of a share and the company's profit

PEG Ratio: N/A

Price/earnings to growth

DPS: N/A

Dividend Per Share is a financial indicator equal to the ratio of the company's net profit available for distribution to the annual average of ordinary shares.

DY: N/A

Dividend yield is a ratio that shows how much a company pays in dividends each year at the stock price.

EPS: N/A

EPS shows how much of the net profit is accounted for by the common share.

Quarterly Earnings Growth YOY: N/A
Quarterly Revenue Growth YOY: N/A
Trailing PE: N/A

Trailing P/E depends on what has already been done. It uses the current share price and divides it by the total earnings per share for the last 12 months.

Forward PE: N/A

Forward P/E uses projections of future earnings instead of final numbers.

EV To Revenue: N/A

Enterprise Value (EV) /Revenue

EV To EBITDA: N/A

The EV / EBITDA ratio shows the ratio of the cost (EV) to its profit before tax, interest and amortization (EBITDA).

Shares Outstanding: N/A

Number of issued ordinary shares

Shares Float: N/A

Number of freely tradable shares

Shares Short Prior Month: N/A

Shares Short Prior Month - the number of shares in short positions in the last month.

Short Ratio: N/A
Percent Insiders: N/A
Percent Institutions: N/A


Related stocks from Healthcare sector


Disclaimer:

All forecast data on the site are provided for informational purposes of using neural forecasting tools in the financial market and are not a call to action and, moreover, are not trading signals. When using the forecast data, the investor assumes all financial risks. The pandaforecast.com portal is not responsible for the loss of your money in the stock market as a result of using the information contained on the site.